Publications
Found 1 results
Filters: Author is M. Najah [Clear All Filters]
“+294T/C polymorphism in the PPAR-δ gene is associated with risk of coronary artery disease in normolipidemic Tunisians”, vol. 9, pp. 1326-1333, 2010.
, Aberle J, Hopfer I, Beil FU and Seedorf U (2006). Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int. J. Med. Sci. 3: 108-111.
http://dx.doi.org/10.7150/ijms.3.108
PMid:16906219 PMCid:1525216
Barish GD, Atkins AR, Downes M, Olson P, et al. (2008). PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 105: 4271-4276.
http://dx.doi.org/10.1073/pnas.0711875105
PMid:18337509 PMCid:2393796
Blaschke F, Takaya Y, Caglayan E and Law RE (2006). Obesity, peroxisome proliferators-activated receptor, and atherosclerosis in type 2 diabetes. Arteriosc. Thromb. Vasc. Biol. 26: 28-40.
http://dx.doi.org/10.1161/01.ATV.0000191663.12164.77
PMid:16239592
Cardon LR and Palmer LJ (2003). Population stratification and spurious allelic association. Lancet 361: 598-604.
http://dx.doi.org/10.1016/S0140-6736(03)12520-2
Chen S, Tsybouleva N, Ballantyne CM and Gotto AM Jr (2004). Effects of PPAR-α, γ and δ haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 4: 61-71.
http://dx.doi.org/10.1097/00008571-200401000-00007
Colhoun HM, McKeigue PM and Davey SG (2003). Problems of reporting genetic associations with complex outcomes. Lancet 361: 865-872.
http://dx.doi.org/10.1016/S0140-6736(03)12715-8
Dressel U, Allen TL, Pippal JB, Rohde PR, et al. (2003). The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol. Endocrinol. 17: 2477-2493.
http://dx.doi.org/10.1210/me.2003-0151
PMid:14525954
Gouni-Berthold I, Giannakidou E, Müller-Wieland D, Faust M, et al. (2005). Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. J. Hypertens. 23: 301-308.
http://dx.doi.org/10.1097/00004872-200502000-00012
PMid:15662218
Kim HJ, Kim MY, Jin H, Kim HJ, et al. (2009). Peroxisome proliferator-activated receptor {delta} regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/ Smad3. Circ. Res. 105: 16-24.
http://dx.doi.org/10.1161/CIRCRESAHA.108.189159
PMid:19461048
Lee CH, Chawla A, Urbiztondo N, Liao D, et al. (2003). Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302: 453-457.
http://dx.doi.org/10.1126/science.1087344
PMid:12970571
Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, et al. (2000). Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett. 473: 333-336.
http://dx.doi.org/10.1016/S0014-5793(00)01554-4
Li AC, Binder CJ, Gutierrez A, Brown KK, et al. (2004). Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114: 1564-1576.
PMid:15578089 PMCid:529277
Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, et al. (2006). Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation. Arterioscler. Thromb. Vasc. Biol. 26: 1481-1487.
http://dx.doi.org/10.1161/01.ATV.0000223875.14120.93
PMid:16645156
Miller SA, Dykes DD and Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
http://dx.doi.org/10.1093/nar/16.3.1215
PMid:3344216 PMCid:334765
Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, et al. (2007). Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27: 63-69.
http://dx.doi.org/10.1161/01.ATV.0000250972.83623.61
PMid:17068288
Rival Y, Beneteau N, Taillandier T, Pezet M, et al. (2002). PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435: 143-151.
http://dx.doi.org/10.1016/S0014-2999(01)01589-8
Seedorf U and Aberle J (2007). Emerging roles of PPARdelta in metabolism. Biochim. Biophys. Acta 1771: 1125-1131.
http://dx.doi.org/10.1016/j.bbalip.2007.04.017
PMid:17588807
Skogsberg J, Kannisto K, Cassel TN, Hamsten A, et al. (2003a). Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler. Thromb. Vasc. Biol. 23: 637-643.
http://dx.doi.org/10.1161/01.ATV.0000064383.88696.24
PMid:12615676
Skogsberg J, McMahon AD, Karpe F, Hamsten A, et al. (2003b). Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J. Intern. Med. 254: 597-604.
http://dx.doi.org/10.1111/j.1365-2796.2003.01236.x
PMid:14641801
Tan NS, Michalik L, Noy N, Yasmin R, et al. (2001). Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 15: 3263-3277.
http://dx.doi.org/10.1101/gad.207501
PMid:11751632 PMCid:312855
Tan NS, Michalik L, Di-Poi N, Desvergne B, et al. (2004). Critical roles of the nuclear receptor PPARbeta (peroxisome-proliferator-activated receptor beta) in skin wound healing. Biochem. Soc. Trans. 32: 97-102.
http://dx.doi.org/10.1042/BST0320097
PMid:14748722
Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, et al. (2003). PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100: 6712-6717.
http://dx.doi.org/10.1073/pnas.1031789100
PMid:12740443 PMCid:164512